AtriCure (NASDAQ:ATRC) Sets New 12-Month High – What’s Next?

Shares of AtriCure, Inc. (NASDAQ:ATRC) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $49.98 and last traded at $47.78, with a volume of 390633 shares changing hands. The stock had previously closed at $48.54.

Analysts Set New Price Targets

Several analysts recently weighed in on ATRC shares. UBS Group cut their price target on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. BTIG Research lifted their price objective on AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, August 24th. Weiss Ratings raised AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 19th. Canaccord Genuity Group increased their target price on AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Finally, Citigroup restated a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $49.89.

AtriCure Trading Down 3.4%

The stock has a market cap of $2.39 billion, a PE ratio of 223.09 and a beta of 1.20. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. The stock’s fifty day moving average price is $37.89 and its 200 day moving average price is $32.22.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The company had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same period in the previous year, the business earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, sell-side analysts forecast that AtriCure, Inc. will post 0.29 EPS for the current year.

Insider Transactions at AtriCure

In other news, Director Sven Wehrwein sold 25,000 shares of the company’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $37.84, for a total transaction of $946,000.00. Following the transaction, the director directly owned 40,518 shares of the company’s stock, valued at $1,533,201.12. This represents a 38.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Vinayak Doraiswamy sold 6,000 shares of the company’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $38.88, for a total value of $233,280.00. Following the transaction, the insider directly owned 86,511 shares in the company, valued at approximately $3,363,547.68. The trade was a 6.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 53,616 shares of company stock valued at $2,149,994. Insiders own 4.00% of the company’s stock.

Institutional Trading of AtriCure

Institutional investors have recently made changes to their positions in the stock. Geneos Wealth Management Inc. purchased a new position in shares of AtriCure during the second quarter valued at approximately $37,000. Harbor Investment Advisory LLC purchased a new stake in AtriCure in the second quarter worth approximately $40,000. Allworth Financial LP purchased a new stake in AtriCure in the second quarter worth approximately $43,000. Smartleaf Asset Management LLC grew its position in AtriCure by 59.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after purchasing an additional 429 shares during the period. Finally, Fifth Third Bancorp bought a new stake in AtriCure in the 1st quarter worth approximately $51,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.